[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Kikuchi M, Kamei S, Morirama Y, Tuchiya T, Miwa K, Yokoi S, Nakano M, Ehara H, Deguchi T, Hirose Y: [Case of urachal cancer treated by neoadjuvant chemotherapy with FOLFOX4 (oxaliplatin, 5-FU and leukovolin)]. Hinyokika Kiyo; 2008 Aug;54(8):557-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of urachal cancer treated by neoadjuvant chemotherapy with FOLFOX4 (oxaliplatin, 5-FU and leukovolin)].
  • A 52-year-old woman was referred to our hospital for treatment of urachal cancer.
  • Computed tomography and magnetic resonance imaging showed a non-papillary sessile tumor, which was located on the dome of the bladder and invaded the small intestine.
  • After three courses of neoadjuvant chemotherapy with FOLFOX4 (oxaliplatin, 5-FU and leukovolin), the tumor was reduced from 7 x 6 cm to 5.5 x 5 cm in size.
  • One course of adjuvant chemotherapy (FOLFOX4) was performed.
  • For 1.5 years after the surgery, no local recurrence or distant metastasis has been observed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Ileal Neoplasms / drug therapy. Neoadjuvant Therapy. Urachus. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Middle Aged. Neoplasm Invasiveness. Organoplatinum Compounds / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Urachal cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18788447.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


2. Hasegawa H, Suzuki R, Nagaoka T, Tezuka Y, Kadota S, Saiki I: Prevention of growth and metastasis of murine melanoma through enhanced natural-killer cytotoxicity by fatty acid-conjugate of protopanaxatriol. Biol Pharm Bull; 2002 Jul;25(7):861-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of growth and metastasis of murine melanoma through enhanced natural-killer cytotoxicity by fatty acid-conjugate of protopanaxatriol.
  • 20(S)-Protopanaxatriol (M4) is the main bacterial metabolite of protopanaxatriol-type ginsenosides and mediates their antitumor effects.
  • Analyses using TLC, HPLC, MS and NMR suggest that orally administered M4 was absorbed from the small intestine into the mesenteric lymphatics followed by the rapid esterification of M4 with fatty acids and its accumulation in the tissues including the liver and lung.
  • The administration of M4 prior to the intravenous injection of B16-BL6 cells abrogated the enhanced lung metastasis in the mice pretreated with 2-chloroadenosine more effectively than in those pretreated with anti-asialo GM1.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Killer Cells, Natural / drug effects. Lung Neoplasms / prevention & control. Melanoma, Experimental / drug therapy. Sapogenins / therapeutic use. Triterpenes / therapeutic use
  • [MeSH-minor] Administration, Oral. Animals. Biological Availability. Cell Survival / drug effects. Cytotoxicity, Immunologic / drug effects. Female. Intestinal Absorption. Intestine, Small / metabolism. Intestine, Small / microbiology. Male. Mice. Mice, Inbred C57BL. Neoplasm Transplantation. Panax / chemistry. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12132658.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Sapogenins; 0 / Triterpenes; 34080-08-5 / protopanaxatriol
  •  go-up   go-down


3. Ulusan S, Koç Z, Kayaselçuk F: Imaging characteristics of liver metastasis from gastrointestinal stromal tumor before and after imatinib mesylate treatment. Turk J Gastroenterol; 2008 Jun;19(2):129-32
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging characteristics of liver metastasis from gastrointestinal stromal tumor before and after imatinib mesylate treatment.
  • Our objective was to show the unusual imaging characteristics of cystic liver metastases from a malignant gastrointestinal stromal tumor before and after treatment with imatinib mesylate.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Stromal Tumors / ultrasonography. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Aged. Benzamides. Colon / pathology. Fatal Outcome. Humans. Imatinib Mesylate. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / ultrasonography. Intestine, Small / pathology. Liver / drug effects. Liver / pathology. Liver / ultrasonography. Male. Neoplasm Invasiveness. Stomach / pathology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110671.001).
  • [ISSN] 2148-5607
  • [Journal-full-title] The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • [ISO-abbreviation] Turk J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


Advertisement
4. Zaanan A, Costes L, Gauthier M, Malka D, Locher C, Mitry E, Tougeron D, Lecomte T, Gornet JM, Sobhani I, Moulin V, Afchain P, Taïeb J, Bonnetain F, Aparicio T: Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. Ann Oncol; 2010 Sep;21(9):1786-93
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.
  • BACKGROUND: Small-bowel adenocarcinoma (SBA) is a rare tumor of poor prognosis.
  • Data on the efficacy of chemotherapy for advanced SBA are scarce.
  • PATIENTS AND METHODS: All patients with advanced SBA who received frontline chemotherapy from 1996 to 2008 were eligible for this retrospective multicenter study.
  • In the entire population, the median progression-free survival (PFS) and overall survival (OS) times were 6.6 and 15.1 months, respectively.
  • Median PFS times among patients treated with LV5FU2 (n = 10), FOLFOX (n = 48), FOLFIRI (n = 19) and LV5FU2-cisplatin (n = 16) were 7.7, 6.9, 6.0 and 4.8 months, respectively, while median OS times were 13.5, 17.8, 10.6 and 9.3 months, respectively.
  • In the subgroup of patients treated with platinum-based chemotherapy, multivariate analysis showed that LV5FU2-cisplatin was associated with poorer PFS (P < 0.0001) and OS (P = 0.02) compared with FOLFOX.
  • CONCLUSIONS: This is the largest study of chemotherapy in advanced SBA.
  • FOLFOX seems to be the most effective platinum-based chemotherapy regimen.

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20223786.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


5. Hung KE, Maricevich MA, Richard LG, Chen WY, Richardson MP, Kunin A, Bronson RT, Mahmood U, Kucherlapati R: Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc Natl Acad Sci U S A; 2010 Jan 26;107(4):1565-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment.
  • Most genetically engineered mouse (GEM) models for colon cancer are based on tissuewide or germline gene modification, resulting in tumors predominantly of the small intestine.
  • We have developed a stochastic somatic mutation model for sporadic colon cancer that presents with isolated primary tumors in the distal colon and recapitulates the entire adenoma-carcinoma-metastasis axis seen in human colon cancer.
  • Because of the restricted location in the distal colon, the natural history of the tumors can be analyzed by serial colonoscopy.
  • As the mammalian target of rapamycin (mTOR) pathway is a critical component of the complex signaling network in colon cancer, we used this model to assess the efficacy of mTOR blockade through rapamycin treatment of mice with established tumors.
  • After treatment, Apc mutant tumors were more than 80% smaller than control tumors.
  • However, tumors that possessed both Apc and Kras mutations did not respond to rapamycin treatment.
  • These studies suggest that mTOR inhibitors should be further explored as potential colorectal cancer therapies in patients whose tumors do not have activating mutations in KRAS.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2001 Oct 4;20(45):6551-8 [11641780.001]
  • [Cites] Cell. 2009 May 15;137(4):623-34 [19450512.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):251-65 [12001987.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):48-54 [14729607.001]
  • [Cites] J Biol Chem. 2004 Oct 8;279(41):43261-72 [15294912.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Cancer Res. 1997 May 15;57(10):1999-2006 [9157997.001]
  • [Cites] Science. 1997 Oct 3;278(5335):120-3 [9311916.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17216-21 [15563600.001]
  • [Cites] Nat Med. 2005 Jan;11(1):63-70 [15619626.001]
  • [Cites] Nature. 2006 May 25;441(7092):424-30 [16724053.001]
  • [Cites] Nat Rev Drug Discov. 2006 Sep;5(9):741-54 [16915232.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14122-7 [16959882.001]
  • [Cites] Gastrointest Endosc. 2006 Oct;64(4):589-97 [16996355.001]
  • [Cites] Gastroenterology. 2006 Oct;131(4):1096-109 [17030180.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2676-84 [17121914.001]
  • [Cites] PLoS Genet. 2006 Sep 15;2(9):e146 [17002498.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):96-102 [17241863.001]
  • [Cites] Nat Protoc. 2006;1(6):2900-4 [17406549.001]
  • [Cites] Cancer Cell. 2007 Apr;11(4):321-33 [17418409.001]
  • [Cites] Radiology. 2007 Jul;244(1):232-8 [17507718.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):9-22 [17613433.001]
  • [Cites] Nat Rev Cancer. 2007 Sep;7(9):645-58 [17687385.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Nat Genet. 2008 May;40(5):600-8 [18372904.001]
  • [Cites] Genes Dev. 2008 Jul 15;22(14):1856-64 [18628392.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13544-9 [18768809.001]
  • [Cites] Nat Med. 2008 Dec;14(12):1351-6 [19029981.001]
  • [Cites] Gastrointest Endosc. 2009 Mar;69(3 Pt 2):742-9 [19251020.001]
  • [Cites] Gastroenterology. 2009 Mar;136(3):780-98 [19263594.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Mar;2(3):224-33 [19240248.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3243-8 [11751630.001]
  • (PMID = 20080688.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK078033; United States / NCI NIH HHS / CA / 5U01CA084301; United States / NCI NIH HHS / CA / U01 CA084301; United States / NCI NIH HHS / CA / 5P50CA127003; United States / NIDDK NIH HHS / DK / P30 DK043351; United States / NIBIB NIH HHS / EB / 5R01EB001872; United States / NIDDK NIH HHS / DK / 5K08DK078033; United States / NIBIB NIH HHS / EB / R01 EB001872; United States / NCI NIH HHS / CA / P50 CA127003
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Intracellular Signaling Peptides and Proteins; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 3.6.5.2 / Kras2 protein, mouse; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC2824379
  •  go-up   go-down


6. Ono M, Shirao K, Takashima A, Morizane C, Okita N, Takahari D, Hirashima Y, Eguchi-Nakajima T, Kato K, Hamaguchi T, Yamada Y, Shimada Y: Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine. Gastric Cancer; 2008;11(4):201-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine.
  • BACKGROUND: Small-bowel adenocarcinoma (SBA) is a rare tumor that has a poor response to chemotherapy and a poor prognosis.
  • Treatment strategies for SBA have not been clearly established.
  • METHODS: All patients with SBA treated using a combination of cisplatin and irinotecan (IP) as first-line chemotherapy at the National Cancer Center Hospital in Japan between January 1999 and February 2007 were studied retrospectively.
  • RESULTS: Eight patients received IP as first-line chemotherapy.
  • The median time to treatment failure was 4.5 months (95% confidence interval, 0.9-5.8 months), and overall survival was 17.3 months (range, 1.9-21.3 months).
  • CONCLUSION: IP combination chemotherapy may be an acceptable option for patients with SBA.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Intestinal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Duodenal Neoplasms / drug therapy. Duodenal Neoplasms / mortality. Female. Humans. Ileal Neoplasms / drug therapy. Ileal Neoplasms / mortality. Jejunal Neoplasms / drug therapy. Jejunal Neoplasms / mortality. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Metastasis / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1998 Aug;78(4):508-10 [9716035.001]
  • [Cites] Oncology (Williston Park). 1997 Apr;11(4):529-36; discussion 545, 549-50 [9130275.001]
  • [Cites] Clin Colorectal Cancer. 2004 Nov;4(4):241-8; discussion 249-51 [15555205.001]
  • [Cites] Oncology. 2005;69(4):290-4 [16282708.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):921-7 [9060529.001]
  • [Cites] Semin Oncol. 1988 Apr;15(2):116-28 [3285475.001]
  • [Cites] J Chemother. 2003 Oct;15(5):503-6 [14598944.001]
  • [Cites] Oncologist. 2005 Feb;10(2):132-7 [15709215.001]
  • [Cites] Am J Clin Oncol. 2006 Jun;29(3):225-31 [16755174.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Jun;31(2):625-39 [12134621.001]
  • [Cites] Cancer. 1984 Jan 1;53(1):23-5 [6690001.001]
  • [Cites] J Clin Oncol. 1999 Jan;17 (1):319-23 [10458249.001]
  • (PMID = 19132481.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0H43101T0J / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. Suckow MA, Hall P, Wolter W, Sailes V, Hiles MC: Use of an extracellular matrix material as a vaccine carrier and adjuvant. Anticancer Res; 2008 Sep-Oct;28(5A):2529-34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because cancer vaccines based on whole cell preparations might benefit from an adjuvant which enhances expression of antigens expressed during tumor cell growth, we evaluated the utility of an extracellular matrix material, porcine small intestinal submucosa (SIS), as a cancer vaccine adjuvant.
  • CONCLUSION: SIS enhanced the efficacy of a tissue vaccine for prostate cancer, demonstrating the potential utility of extracellular matrices as novel vaccine adjuvants.
  • [MeSH-major] Adenocarcinoma / immunology. Adenocarcinoma / therapy. Adjuvants, Immunologic / pharmacology. Cancer Vaccines / pharmacology. Prostatic Neoplasms / immunology. Prostatic Neoplasms / therapy
  • [MeSH-minor] Animals. Cell Growth Processes / drug effects. Cell Growth Processes / immunology. Extracellular Matrix / chemistry. Extracellular Matrix / immunology. Glutaral / pharmacology. Intestinal Mucosa / chemistry. Intestinal Mucosa / immunology. Intestine, Small / chemistry. Intestine, Small / immunology. Male. Neoplasm Metastasis. Rats. Rats, Wistar. Swine

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Glutaraldehyde .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035274.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Cancer Vaccines; T3C89M417N / Glutaral
  •  go-up   go-down


8. Suenaga M, Mizunuma N, Chin K, Matsusaka S, Shinozaki E, Oya M, Ueno M, Yamaguchi T, Muto T, Konishi F, Hatake K: Chemotherapy for small-bowel Adenocarcinoma at a single institution. Surg Today; 2009;39(1):27-31
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for small-bowel Adenocarcinoma at a single institution.
  • PURPOSE: Small-bowel adenocarcinoma (SBA) is rare.
  • No standard chemotherapy for this type of cancer has yet been established.
  • At Cancer Institute Hospital (CIH), the chemotherapy regimen used for colorectal cancer is initially used for patients with SBA, followed by that used for gastric cancer.
  • METHODS: Patients with advanced or recurrent SBA who had been treated with chemotherapy in CIH were retrospectively analyzed.
  • The first-line treatments were fluoropyrimidines used alone or in combination with other drugs, such as 5-fluorouracil plus leucovorin (FL), UFT-E, or TS-1.
  • The second-line treatment was irinotecan (CPT-11) monotherapy.
  • Disease control was seen in five patients (50%) with the first-line chemotherapy and in three (43%) with the second-line.
  • The median overall survival time was 12 months (range 3-39).
  • The treatments were generally tolerated.
  • CONCLUSIONS: Fluoropyrimidines as the first-line and CPT-11 as the second-line chemotherapy yielded low response, although the adverse effects were mild.
  • Extensive trials are needed to develop standard chemotherapy with new drugs.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Disease Progression. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Follow-Up Studies. Humans. Intestine, Small / diagnostic imaging. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Vitamin B Complex / administration & dosage. Vitamin B Complex / adverse effects

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1998 Aug;78(4):508-10 [9716035.001]
  • [Cites] Am J Surg. 1978 Apr;135(4):601-3 [637208.001]
  • [Cites] Am J Surg. 1987 Apr;153(4):350-4 [3565678.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] Am J Surg. 1986 Jun;151(6):654-8 [2424326.001]
  • [Cites] Surg Today. 1997;27(1):60-3 [9035302.001]
  • [Cites] Arch Surg. 2002 May;137(5):564-70; discussion 570-1 [11982470.001]
  • [Cites] Oncology. 2005;69(4):290-4 [16282708.001]
  • [Cites] Surg Clin North Am. 1986 Aug;66(4):779-85 [3738698.001]
  • [Cites] Semin Oncol. 1988 Apr;15(2):116-28 [3285475.001]
  • [Cites] J Chemother. 2003 Oct;15(5):503-6 [14598944.001]
  • [Cites] Oncologist. 2005 Feb;10(2):132-7 [15709215.001]
  • [Cites] Jpn J Clin Oncol. 2004 Jun;34(6):316-22 [15333683.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Am J Surg. 1980 Sep;140(3):396-9 [7425215.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13-47 [10758303.001]
  • [Cites] Ann Surg Oncol. 1994 Jul;1(4):290-5 [7850527.001]
  • [Cites] Cancer. 1984 Jan 1;53(1):23-5 [6690001.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • (PMID = 19132464.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0H43101T0J / irinotecan; 12001-76-2 / Vitamin B Complex; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


9. Hayashi M, Ueda Y, Takimoto T, Ohkura T: Undifferentiated endometrial carcinoma of the uterus: marked effect of chemotherapy with tetrahydropyranyl-adriamycin, paclitaxel, and carboplatin. Int J Gynecol Cancer; 2004 Mar-Apr;14(2):388-94
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Undifferentiated endometrial carcinoma of the uterus: marked effect of chemotherapy with tetrahydropyranyl-adriamycin, paclitaxel, and carboplatin.
  • To date, there is no consensus as to the optimal chemotherapy for this carcinoma.
  • We report a rare case of this carcinoma in a patient who was treated surgically in combination with chemotherapy using a regimen designed by us.
  • This chemotherapy consists of tetrahydropyranyl-adriamycin, paclitaxel, and carboplatin.
  • This regimen is called TTJ [tetrahydropryanyl-adriamycin, taxan (paclitaxel), JM-8 (carboplatin)] chemotherapy and showed a marked effect.
  • She underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy and omentectomy, but residual carcinoma remained on the surface of the small intestine.
  • Pathologically tumor tissues comprised the whole uterus except for the uterine cervix and there were tumor tissues in the omentum.
  • She was treated with six courses of TTJ chemotherapy without major side-effects.
  • Currently, she remains alive without metastasis 41 months after hysterectomy.
  • This report describes a rare case of undifferentiated endometrial carcinoma of the uterus and introduces TTJ chemotherapy resulting in the remarkable effect on this carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / drug therapy. Uterine Neoplasms / diagnosis. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Combined Modality Therapy. Diagnosis, Differential. Doxorubicin / administration & dosage. Female. Humans. Hysterectomy. L-Lactate Dehydrogenase / blood. Magnetic Resonance Imaging. Middle Aged. Neoplasm, Residual. Ovariectomy. Paclitaxel / administration & dosage

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15086745.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; EC 1.1.1.27 / L-Lactate Dehydrogenase; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


10. Chen ZY, Ma YB, Sheng XG, Zhang XL, Xue L, Song QQ, Liu NF, Miao HQ: [Intensity modulated radiation therapy for patients with gynecological malignancies after hysterectomy and chemotherapy/radiotherapy]. Zhonghua Zhong Liu Za Zhi; 2007 Apr;29(4):305-8
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intensity modulated radiation therapy for patients with gynecological malignancies after hysterectomy and chemotherapy/radiotherapy].
  • OBJECTIVE: To investigate the value of intensity modulated radiation therapy (IMRT) for patient with gynecological malignancies after treatment of hysterectomy and chemotherapy/radiotherapy.
  • METHODS: All 32 patients with cervical or endometrial cancer after hysterectomy received full course IMRT after 1 to 3 cycles of chemotherapy (Karnofsky performance status(KPS) > or =70).
  • Seventeen of these patients underwent postoperative preventive irradiation and the other 15 patients were pelvic wall recurrence and/or retroperitoneal lymph node metastasis, though postoperative radiotherapy and/or chemotherapy had been given after operation.
  • RESULTS: The median dose delivered to the PTV was 56.8 Gy for preventive irradiation, and 60.6 Gy for pelvic wall recurrence or retroperioneal lymph node metastasis irradiation.
  • However, The mean dose irradiated to small intestine, bladder, rectum, kidney and spinal cord was 21.3 Gy, 37.8 Gy, 35.3 Gy, 8.5 Gy, 22.1 Gy, respectively.
  • Fourteen patients presented grade I (11 patients) or II (3 patients) digestive tract side-effects, Five patients developed grade I or II bone marrow depression.
  • The 2- and 3- year survival rate for preventive irradiation were both 100%, but which was 5/7 and 3/6 for the patients with pelvic wall recurrence or retroperioneal lymph node metastasis.
  • CONCLUSION: Intensity modulated radiation therapy can provide a better dose distribution than traditional radiotherapy for both prevention and pelvic wall recurrence or retroperioneal lymph node metastasis.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Diarrhea / etiology. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy Dosage. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17760262.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


11. Huang CC, Yang CY, Lai IR, Chen CN, Lee PH, Lin MT: Gastrointestinal stromal tumor of the small intestine: a clinicopathologic study of 70 cases in the postimatinib era. World J Surg; 2009 Apr;33(4):828-34
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumor of the small intestine: a clinicopathologic study of 70 cases in the postimatinib era.
  • BACKGROUND: The small intestine, after the stomach, is the second most common primary site for gastrointestinal stromal tumors (GISTs).
  • This study aimed to identify clinicopathologic prognostic factors of tumor recurrence and survival and to analyze the influence of imatinib and sunitinib for small-intestine GISTs.
  • METHODS: We reviewed the surgical experience of patients with small-intestine GISTs at National Taiwan University Hospital from January 1995 to March 2007.
  • We analyzed the perioperative clinicopathologic data and treatment course.
  • The tumor was local in 43 patients, advanced in 21 patients, and 6 had metastasis.
  • CONCLUSIONS: The invasion status, size, and mitotic rate of tumor involve higher risk of recurrence and poor survival in small-intestine GISTs.
  • The patients with recurrent small-intestine GISTs may have a lower mortality rate after using imatinib and sunitinib.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Disease-Free Survival. Duodenal Neoplasms / drug therapy. Duodenal Neoplasms / pathology. Female. Gastrointestinal Agents / therapeutic use. Humans. Ileal Neoplasms / drug therapy. Ileal Neoplasms / pathology. Infliximab. Jejunal Neoplasms / drug therapy. Jejunal Neoplasms / pathology. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Ann Surg Oncol. 2001 Jan-Feb;8(1):50-9 [11206225.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):477-89 [16625094.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3034-8 [12374669.001]
  • [Cites] Am J Surg Pathol. 1983 Sep;7(6):507-19 [6625048.001]
  • [Cites] Dig Surg. 2008;25(3):208-12 [18577866.001]
  • [Cites] Am Surg. 2006 Aug;72(8):719-22; discussion 722-3 [16913316.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Am J Clin Pathol. 1997 Dec;108(6):641-51 [9384445.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1259-69 [9588894.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):407-16 [9130987.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] Mod Pathol. 1997 Mar;10(3):200-9 [9071727.001]
  • [Cites] BMC Gastroenterol. 2006 Oct 24;6:29 [17062131.001]
  • [Cites] J Formos Med Assoc. 2005 Dec;104(12):905-12 [16607447.001]
  • (PMID = 19198935.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Gastrointestinal Agents; B72HH48FLU / Infliximab
  •  go-up   go-down


12. Overman MJ, Kopetz S, Lin E, Abbruzzese JL, Wolff RA: Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol; 2010 May;49(4):474-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine.
  • BACKGROUND: The benefit of adjuvant therapy for resected small bowel adenocarcinoma has not been proven.
  • We undertook a retrospective analysis to evaluate the benefit of adjuvant therapy in a clearly defined patient population with curatively resected small bowel adenocarcinoma.
  • MATERIAL AND METHODS: We identified 54 patients with small bowel adenocarcinoma who underwent margin-negative surgical resection and were evaluated after surgery at the University of Texas, M. D.
  • Thirty patients (56%) received adjuvant therapy consisting of systemic chemotherapy with or without radiation in 28 and radiation alone in two.
  • Patients who received adjuvant therapy had significantly higher tumor stage and rate of lymph node involvement.
  • Five-year DFS and OS did not differ between treatment groups.
  • In multivariate analysis, the use of adjuvant therapy was associated with improved DFS (HR 0.27; 95% CI 0.07-0.98, P = 0.05) but not OS (HR 0.47; 95% CI 0.13-1.62, P = 0.23).
  • In patients with a high risk of relapse (defined as a lymph node ratio >or=10%), adjuvant therapy appeared to improve OS, P = 0.04, but not DFS, P = 0.15.
  • DISCUSSION: The use of adjuvant therapy for curatively resected small bowel adenocarcinoma was associated with an improvement in DFS.
  • This finding strongly supports further investigation of adjuvant chemotherapy in this tumor type.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / therapy. Intestine, Small
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Chemotherapy, Adjuvant. Disease-Free Survival. Duodenal Neoplasms / therapy. Female. Follow-Up Studies. Humans. Ileal Neoplasms / therapy. Jejunal Neoplasms / therapy. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20397775.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


13. Mazaki T, Mado K, Manmoto J, Okame H, Ishii Y, Suzuki K, Masuda H, Takayama T: [Three cases with liver metastasis from gastric or colon cancer successfully treated with S-1 combined with CPT- 11]. Gan To Kagaku Ryoho; 2008 Sep;35(9):1583-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three cases with liver metastasis from gastric or colon cancer successfully treated with S-1 combined with CPT- 11].
  • We report three cases with liver metastasis from gastric or colon cancer successfully treated with S-1 with CPT-11.
  • Case 1: A total gastrectomy was performed for a gastric cancer located in the lower to upper body of the stomach (T3 (SE), N2, H0, P0, por 2, stage III B).
  • Abdominal computed-tomography (CT) revealed a solitary liver metastasis in the S8 subsegment of the liver.
  • Case 2: Sigmoidectomy and partial resection of small intestine and abdominal wall were performed for sigmoid colon cancer.
  • Case 3: Laparoscopic right hemicolectomy was performed for ascending colon cancer (SE, N1, H0, P0, M0, tub 1, stage III a).
  • Abdominal CT showed a solitary liver metastasis in the S6 subsegment of the liver 3 months after surgery.
  • [MeSH-major] Camptothecin / analogs & derivatives. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Combinations. Female. Humans. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18799916.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


14. Hagiwara A, Sakakura C, Shirasu M, Togawa T, Sonoyama Y, Fujiyama J, Ebihara Y, Itoh T, Yamagishi H: Intraperitoneal injection of dextran sulfate as an anti-adherent drug for the prevention of peritoneal metastasis of cancer shows low toxicity in animals. Anticancer Drugs; 2000 Jun;11(5):393-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal injection of dextran sulfate as an anti-adherent drug for the prevention of peritoneal metastasis of cancer shows low toxicity in animals.
  • Intraperitoneal dextran sulfate with a mean molecular weight of 5 x 10(5) has been developed for use in an anti-adherent therapy against peritoneal carcinomatosis.
  • These results suggest that the i.p. dextran sulfate is safe as an anti-adherent agent against peritoneal metastasis of cancer.
  • [MeSH-minor] Animals. Blood Chemical Analysis. Body Weight / drug effects. Cell Adhesion / drug effects. Injections, Intraperitoneal. Intestine, Small / drug effects. Lethal Dose 50. Male. Mice. Neoplasm Metastasis / prevention & control. Rabbits

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10912956.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 9042-14-2 / Dextran Sulfate
  •  go-up   go-down


15. Zhan WH, Wang PZ, Shao YF, Wu XT, Gu J, Li R, Wan DS, Ding KF, Shi YQ, Yu JR, Lu HS, Zou XM, Bi JW, Sun YH, Lu YF, Chen DD, Zhang XH: [Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial]. Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Sep;9(5):383-7
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial].
  • OBJECTIVE: To evaluate the efficacy and safety of postoperative adjuvant chemotherapy with imatinib in gastrointestinal stromal tumor(GIST) patients who had high risk of recurrence.
  • The criteria of the enrolled patients included age more than 18 years old, CD117 positive GIST, tumor size more than 5 cm, pathological mitosis counts more than 5/50 HPF, and treatment beginning within 4 weeks after complete resection and with imatinib (400 mg, once a day) for at least 12 months.
  • 13th 2005, there were totally 74 patients screened and 57 patients (34 men, 23 women) enrolled in the imatinib treatment group.
  • The primary tumors were located in the stomach in 50.9%, the small intestine in 38.6% and the colorectum in 10.5% of the cases.
  • Until the cut-off date of interim analysis, there was no evidence of tumor relapse or metastasis in all patients and no death was reported either.
  • CONCLUSION: Imatinib is a promising postoperative adjuvant chemotherapy in GISTs patients with high risk of recurrence, and the adverse effects are receivable.
  • [MeSH-major] Gastrointestinal Stromal Tumors / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Benzamides. Chemotherapy, Adjuvant. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Neoplasm Recurrence, Local. Postoperative Period. Prospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17043955.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


16. Dörffel Y, Wermke W: Neuroendocrine tumors: characterization with contrast-enhanced ultrasonography. Ultraschall Med; 2008 Oct;29(5):506-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NET of the small intestine and pancreas represented hypoechoic, isoechoic, and/or hyperechoic liver lesions, sometimes combined.
  • Necrotic areas (25/83) were detected after interferon therapy, embolization, systemic chemotherapy, and radiofrequency ablation of liver metastases, but did not develop after somatostatin receptor radionuclide therapy.
  • The hypervascularized tissue was found in the primary lesions, in liver, lymph node metastases and any kind of abdominal metastases.
  • In most cases real-time CEUS may replace other imaging techniques.
  • [MeSH-minor] Adult. Carcinoid Tumor / pathology. Carcinoid Tumor / ultrasonography. Humans. Jejunal Neoplasms / secondary. Jejunal Neoplasms / ultrasonography. Liver Neoplasms / secondary. Liver Neoplasms / ultrasonography. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Metastasis / ultrasonography. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / ultrasonography. Sensitivity and Specificity. Ultrasonography / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241507.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


17. Kimura Y, Sumiyoshi M, Taniguchi M, Baba K: Antitumor actions of a chromone glucoside cnidimoside A isolated from Cnidium japonicum. J Nat Med; 2008 Jul;62(3):308-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we examined the effects of a chromone glucoside cnidimoside A isolated from Cnidium japonicum whole plants on tumor growth and tumor metastasis in colon 26-bearing mice.
  • In this study, the CD8(+) T Cell- and interferon (IFN)-gamma-positive cell numbers in the small intestine in the colon 26-bearing mice were significantly reduced compared with those in the normal mice, but the natural killer (NK)-positive cell number did not differ significantly between the normal and colon 26-bearing mice.
  • The CD8(+) T-, NK and IFN-gamma-positive cell numbers in the small intestine were significantly increased by orally administered cnidimoside A (50 mg/kg, twice daily) compared to those in vehicle-treated colon 26-bearing mice.
  • In conclusion, it seems likely that the antitumor and antimetastatic actions of cnidimoside A may be partly associated with the stimulation of immune response in the small intestine.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Chromones / pharmacology. Cnidium / chemistry. Colonic Neoplasms / drug therapy. Glucosides / pharmacology
  • [MeSH-minor] Administration, Oral. Animals. CD8-Positive T-Lymphocytes / drug effects. CD8-Positive T-Lymphocytes / metabolism. Cell Line, Tumor. Drug Screening Assays, Antitumor. Endothelium, Vascular / drug effects. Endothelium, Vascular / metabolism. Humans. Interferon-gamma / drug effects. Interferon-gamma / metabolism. Intestine, Small / drug effects. Intestine, Small / pathology. Killer Cells, Natural / drug effects. Killer Cells, Natural / metabolism. Male. Mice. Mice, Inbred BALB C. Neoplasm Metastasis / drug therapy. Umbilical Veins / drug effects. Umbilical Veins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nutr. 2001 Jun;131(6):1844-9 [11385077.001]
  • [Cites] Jpn J Cancer Res. 2000 Oct;91(10):1022-7 [11050473.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):429-37 [12845685.001]
  • [Cites] Cancer Res. 1991 Feb 15;51(4):1124-8 [1705166.001]
  • [Cites] J Pediatr Surg. 2007 Jan;42(1):1-11 [17208533.001]
  • [Cites] J Immunol. 2003 Jul 15;171(2):608-15 [12847225.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):594-607 [16376330.001]
  • [Cites] Planta Med. 2004 Mar;70(3):211-9 [15114497.001]
  • [Cites] J Biol Chem. 1992 Jun 5;267(16):10931-4 [1375931.001]
  • [Cites] Clin Exp Metastasis. 1999 Feb;17(1):35-40 [10390145.001]
  • [Cites] Annu Rev Physiol. 1991;53:217-39 [1710435.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2774-8 [8464888.001]
  • [Cites] J Exp Med. 1998 Dec 21;188(12):2357-68 [9858522.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] J Immunol. 2002 Jan 1;168(1):1-4 [11751938.001]
  • [Cites] Cancer Sci. 2005 Jul;96(7):441-50 [16053516.001]
  • [Cites] Immunol Today. 1994 Feb;15(2):48-51 [8155261.001]
  • [Cites] Science. 1987 Jan 23;235(4787):442-7 [2432664.001]
  • [Cites] Cancer Immunol Immunother. 1997 Oct;45(2):100-8 [9390201.001]
  • (PMID = 18418697.001).
  • [ISSN] 1861-0293
  • [Journal-full-title] Journal of natural medicines
  • [ISO-abbreviation] J Nat Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Chromones; 0 / Glucosides; 0 / cnidimoside A; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


18. Salamanca J, Nevado M, Martínez-González MA, Pérez-Espejo G, Pinedo F: Undifferentiated carcinoma of the jejunum with extensive rhabdoid features. Case report and review of the literature. APMIS; 2008 Oct;116(10):941-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant rhabdoid tumor, first described in the kidney of young infants, is a rare and highly aggressive neoplasm of controversial histogenesis that has been reported at many other sites, including the gastrointestinal tract.
  • However, malignant rhabdoid tumor of the small intestine is very rare, with only seven cases published to date.
  • The patient underwent partial jejunectomy and biopsy of a liver metastasis.
  • Immunohistochemically, the neoplasm coexpressed vimentin and epithelial antigens (AE1/AE3, Cam 5.2, CK34betaE12, CK19 and EMA), most of them showing a peculiar immunostaining pattern in relation to the globular inclusions.
  • The patient received postoperative chemotherapy but died 9 months after surgery.
  • As with tumors at other sites, recognition of rhabdoid morphology in small intestine neoplasms is of significance because the prognosis is extremely poor.
  • [MeSH-minor] Aged. Anion Exchange Protein 1, Erythrocyte / analysis. Anion Exchange Protein 1, Erythrocyte / metabolism. Biomarkers / analysis. Biomarkers / metabolism. Biopsy. Cell Nucleolus / pathology. Fatal Outcome. Humans. Hyalin / metabolism. Immunohistochemistry. Inclusion Bodies / metabolism. Inclusion Bodies / pathology. Jejunum / metabolism. Jejunum / pathology. Keratins / analysis. Keratins / metabolism. Liver / pathology. Male. Neoplasm Proteins / analysis. Neoplasm Proteins / metabolism. Vimentin / analysis. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19132990.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anion Exchange Protein 1, Erythrocyte; 0 / Biomarkers; 0 / CAM 5.2 antigen; 0 / CK-34 beta E12; 0 / Neoplasm Proteins; 0 / Vimentin; 68238-35-7 / Keratins
  • [Number-of-references] 8
  •  go-up   go-down


19. Debono M, Hon LQ, Bax N, Blakeborough A, Newell-Price J: Gluteal nodules in patients with metastatic midgut carcinoid disease treated with depot somatostatin analogs. J Clin Endocrinol Metab; 2008 May;93(5):1860-4
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT AND OBJECTIVES: We were referred a patient with metastatic well-differentiated endocrine tumor of the small intestine (midgut carcinoid) in whom asymptomatic sc gluteal nodules had been identified on routine abdominal computed tomography and labeled as metastases.
  • METHODS: Routine abdominal computed tomography scans of 56 patients with metastatic midgut carcinoid were analyzed by two independent radiologists, blinded to treatment status (depot somatostatin analogs).
  • RESULTS: No nodules were detected in 13 patients not on depot somatostatin therapy.
  • Nodules were found in 29 of 43 patients (67%) on somatostatin analog therapy: 16 of 22 patients on lanreotide Autogel, five of 12 patients on octreotide LAR only, and eight of nine patients who had been treated with both somatostatin analogs.
  • Presence of nodules was significantly associated with total number of injections (P = 0.024), duration on treatment (P = 0.022), and cumulative dose of lanreotide Autogel (P < 0.001).
  • CONCLUSION: Patients with metastatic midgut carcinoid tumors have large numbers of asymptomatic sc nodules in the gluteal area when on either depot somatostatin analog, but these resolve over time.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Carcinoid Tumor / drug therapy. Intestinal Neoplasms / drug therapy. Octreotide / adverse effects. Peptides, Cyclic / adverse effects. Radiography, Abdominal. Somatostatin / analogs & derivatives
  • [MeSH-minor] Buttocks. Cross-Sectional Studies. Delayed-Action Preparations. Humans. Neoplasm Metastasis. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18303072.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Delayed-Action Preparations; 0 / Peptides, Cyclic; 118992-92-0 / lanreotide; 51110-01-1 / Somatostatin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


20. Marnitz S, Stromberger C, Kawgan-Kagan M, Wlodarczyk W, Jahn U, Schneider A, Ulrich U, Budach V, Köhler C: Helical tomotherapy in cervical cancer patients: simultaneous integrated boost concept: technique and acute toxicity. Strahlenther Onkol; 2010 Oct;186(10):572-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients were treated with five weekly fractions of 1.8 Gy to a total dose of 50.4 Gy to the tumor region and the pelvic (para-aortic) lymph node region (PTV-A), and five weekly fractions of 2.12 Gy to a total dose of 59.36 Gy to the PTV-B.
  • Chemotherapy consisted of weekly cisplatin 40 mg/m(2).
  • The mean dose to the bladder, rectum, and small bowel was 47.85 Gy, 45.76 Gy, and 29.71 Gy, respectively.
  • [MeSH-minor] Adult. Aged. Dose Fractionation. Female. Humans. Intestine, Small / diagnostic imaging. Laparoscopy. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Staging. Radiation Injuries / etiology. Radiation Injuries / pathology. Radiotherapy / adverse effects. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted / methods. Rectum / diagnostic imaging. Tomography, X-Ray Computed / methods. Urinary Bladder / diagnostic imaging

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2008 Sep;184(9):473-7 [19016026.001]
  • [Cites] Cancer J. 2008 May-Jun;14(3):200-6 [18536561.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Feb 1;37(3):731-6 [9112473.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):176-83 [11777636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):413-8 [17904305.001]
  • [Cites] Strahlenther Onkol. 2009 Dec;185(12):821-9 [20013092.001]
  • [Cites] Strahlenther Onkol. 1998 Oct;174(10):504-9 [9810317.001]
  • [Cites] Strahlenther Onkol. 2009 May;185(5):282-7 [19440666.001]
  • [Cites] Strahlenther Onkol. 2002 Feb;178(2):71-7 [11942040.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):855-66 [10386643.001]
  • [Cites] Radiother Oncol. 2003 Sep;68(3):217-26 [13129628.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):536-44 [16126259.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1613-21 [11121668.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1339-48 [10334517.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1476-80 [19231097.001]
  • [Cites] Int J Gynecol Cancer. 2009 Feb;19(2):194-201 [19395993.001]
  • [Cites] Strahlenther Onkol. 2009 Dec;185(12):799-807 [20013089.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1154-61 [10202166.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):187-93 [10926801.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1137-43 [10202164.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1144-53 [10202165.001]
  • [Cites] Lancet. 2001 Sep 8;358(9284):781-6 [11564482.001]
  • [Cites] Gynecol Oncol. 2007 Oct;107(1 Suppl 1):S241-7 [17826824.001]
  • [Cites] J Clin Oncol. 2008 Dec 10;26(35):5802-12 [19001332.001]
  • [Cites] Strahlenther Onkol. 2009 Mar;185(3):177-83 [19330295.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):261-6 [11516876.001]
  • [Cites] Semin Radiat Oncol. 2006 Jul;16(3):138-43 [16814153.001]
  • [Cites] Strahlenther Onkol. 2008 Nov;184(11):586-91 [19016017.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1438-44 [17394944.001]
  • [Cites] Strahlenther Onkol. 2007 Sep;183(9):473-8 [17762920.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):935-43 [18164828.001]
  • (PMID = 20936458.001).
  • [ISSN] 1439-099X
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Hoffman A, Qadri B, Frant J, Katz Y, Bhusare SR, Breuer E, Hadar R, Reich R: Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis. J Med Chem; 2008 Mar 13;51(5):1406-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • cis-2-Aminocyclohexylcarbamoylphosphonic acid ( cis-ACCP) was evaluated in vitro and in two in vivo cancer metastasis models.
  • It reduced metastasis formation in mice by approximately 90% when administered by a repetitive once daily dosing regimen of 50 mg/kg via oral or intraperitoneal routes and was nontoxic up to 500 mg/kg, following intraperitoneal administration daily for two weeks.
  • Sustained and prolonged absorption ( t 1/2 approximately 126 min) occurred via paracellular mechanism along the small and large intestine with overall bioavailability of 0.3%.
  • [MeSH-minor] Animals. Biological Availability. Cell Line, Tumor. Cyclohexanes. Female. Humans. In Vitro Techniques. Intestinal Absorption. Male. Melanoma, Experimental / drug therapy. Melanoma, Experimental / pathology. Mice. Mice, Inbred C57BL. Mice, SCID. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Transplantation. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology. Rats. Structure-Activity Relationship. Tissue Distribution. Toxicity Tests, Acute

  • COS Scholar Universe. author profiles.
  • BindingDB. BindingDB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Med Chem. 2008 Jul 24;51(14):4357-8
  • (PMID = 18257543.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-aminocyclohexylcarbamoylphosphonic acid; 0 / Antineoplastic Agents; 0 / Cyclohexanes; 0 / Matrix Metalloproteinase Inhibitors; 0 / Organophosphonates
  •  go-up   go-down


22. Tsuda H, Sekine K, Fujita K, Ligo M: Cancer prevention by bovine lactoferrin and underlying mechanisms--a review of experimental and clinical studies. Biochem Cell Biol; 2002;80(1):131-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Marked increase in the number of cytotoxic T and NK cells in the mucosal layer of the small intestine and peripheral blood cells was thus found, this in turn enhancing the production of Interleukin 18 (IL-18) and caspase-1 in the epithelial cells of the small intestine, with possible consequent induction of interferon (IFN)-gamma positive cells.
  • [MeSH-major] Lactoferrin / pharmacology. Lactoferrin / therapeutic use. Neoplasms / drug therapy. Neoplasms / prevention & control
  • [MeSH-minor] Animals. Antiviral Agents / therapeutic use. Clinical Trials as Topic. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Colonic Neoplasms / prevention & control. Hepatitis C, Chronic / drug therapy. Hepatitis C, Chronic / virology. Humans. Immunity, Mucosal / drug effects. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Neoplasm Metastasis / prevention & control. Pilot Projects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11908637.001).
  • [ISSN] 0829-8211
  • [Journal-full-title] Biochemistry and cell biology = Biochimie et biologie cellulaire
  • [ISO-abbreviation] Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antiviral Agents; EC 3.4.21.- / Lactoferrin
  • [Number-of-references] 35
  •  go-up   go-down


23. Sakakibara T, Kurasawa T, Narumi K, Kamano T, Tsurumaru M: T-cell malignant lymphoma of the ileum causing ileac fistulas: report of a case. Surg Today; 2002;32(6):536-40
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell malignant lymphoma of the ileum causing ileac fistulas: report of a case.
  • We herein present a rare case of three fistulas caused by a recurrence of T-cell lymphoma of the ileum.
  • Upper and lower gastrointestinal examinations did not reveal any abnormal findings, but an abdominal aortic aneurysm was diagnosed by computed tomography, and thus was determined to be the source of the pain.
  • The patient was referred to our hospital to undergo a grafting operation; however, a laparotomy performed in July 1997 revealed an unexpected small intestinal tumor, and therefore a partial ileectomy between 15 and 70cm in an oral direction from the terminal ileum was carried out instead.
  • Histopathological and genetic examinations demonstrated diffuse small malignant lymphocytic T-cell lymphomas of the ileum invading all layers.
  • Metastasis of the facial skin and local recurrence were recognized 5 months later, and chemotherapy with THP-COP and ESHAP only resulted in progressive disease.
  • An ileac fistula was found to have formed between the intestine and abdominal wall in March 1998, and the patient died in May 1998.
  • [MeSH-minor] Aged. Fatal Outcome. Humans. Male. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12107782.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 10
  •  go-up   go-down


24. Fonteyne V, De Gersem W, De Neve W, Jacobs F, Lumen N, Vandecasteele K, Villeirs G, De Meerleer G: Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer. Int J Radiat Oncol Biol Phys; 2009 Nov 15;75(4):1013-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
  • METHODS AND MATERIALS: A total of 31 patients with Stage T1-T4N1M0 prostate cancer were treated with intensity-modulated arc radiotherapy and 3 years of androgen deprivation as primary treatment.
  • A median dose of 69.3 Gy and 50 Gy was prescribed to the PTV(p) and PTV(e) respectively, to be delivered in 25 fractions.
  • Upper and lower gastrointestinal toxicity was scored using the Radiation Therapy Oncology Group toxicity and radiotherapy-induced lower intestinal toxicity scoring system.
  • Genitourinary toxicity was scored using a combined Radiation Therapy Oncology Group, LENT-SOMA (late effects normal tissue-subjective, objective, management, analytic), and Common Toxicity Criteria toxicity scoring system.
  • RESULTS: The median follow-up time was 3 months.
  • The mean prescription dose to the CTV(p) and PTV(p) was 70.4 Gy and 68.6 Gy, respectively.
  • The minimal dose to the CTV(e) and PTV(e) was 49.0 Gy and 47.0 Gy, respectively.
  • Fourteen patients developed acute Grade 2 lower gastrointestinal toxicity.
  • Acute Grade 3 and 2 genitourinary toxicity developed in 2 and 14 patients, respectively.
  • CONCLUSION: The results of our study have shown that hypofractionated intensity-modulated arc radiotherapy as primary therapy for N1 prostate cancer is feasible with low toxicity.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / adverse effects
  • [MeSH-minor] Aged. Dose Fractionation. Follow-Up Studies. Humans. Intestine, Large / radiation effects. Intestine, Small / radiation effects. Lymphatic Metastasis / radiotherapy. Male. Middle Aged. Neoplasm Staging. Prostate / radiation effects. Radiation Injuries / pathology. Radiotherapy Planning, Computer-Assisted. Seminal Vesicles / radiation effects. Tumor Burden. Urogenital System / radiation effects

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19386427.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists
  •  go-up   go-down






Advertisement